In8Bio (INAB) Income towards Parent Company (2020 - 2026)
In8Bio (INAB) posted Income towards Parent Company of -$5.1 million for Q1 2026, down 5.38% sequentially from -$4.9 million in Q4 2025, and up 47.93% YoY from -$3.5 million in Q1 2025.
In8Bio (INAB) Income towards Parent Company (2020 - 2026) Analysis & Trends
In8Bio has reported Income towards Parent Company for 7 years, with the latest figure at -$5.1 million in Q1 2026.
- Quarterly Income towards Parent Company rose 47.93% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.1 million (up 68.58% YoY) and the FY2025 annual result came in at -$46.6 million, up 15.83% from the prior year.
- Income towards Parent Company declined to -$5.1 million in Q1 2026 per INAB's latest filing, from -$4.9 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$4.4 million in Q3 2025 and troughed at -$31.3 million in Q4 2024.
- A 5-year average of -$11.2 million and a median of -$9.0 million in 2023 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company slumped 252.18% in 2022, then soared 84.5% in 2025.
- Over 5 years, Income towards Parent Company stood at -$8.7 million in 2022, then sank by 214.65% to -$27.2 million in 2023, then decreased by 14.87% to -$31.3 million in 2024, then jumped by 84.5% to -$4.9 million in 2025, then declined by 5.38% to -$5.1 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$5.1 million, -$4.9 million, and -$4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.01 Mn |
| Mar 31, 2026 | -5.11 Mn |
| Dec 31, 2025 | -4.85 Mn |
| Sep 30, 2025 | -4.42 Mn |
| Jun 30, 2025 | -5.67 Mn |
| Mar 31, 2025 | -9.82 Mn |
| Dec 31, 2024 | -31.29 Mn |
| Sep 30, 2024 | -8.38 Mn |
| Jun 30, 2024 | -14.32 Mn |
| Mar 31, 2024 | -9.90 Mn |
| Dec 31, 2023 | -27.24 Mn |
| Sep 30, 2023 | -12.10 Mn |
| Jun 30, 2023 | -9.51 Mn |
| Mar 31, 2023 | -8.97 Mn |
| Dec 31, 2022 | -8.66 Mn |
| Sep 30, 2022 | -13.47 Mn |
| Jun 30, 2022 | -7.64 Mn |
| Mar 31, 2022 | -8.32 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -5.76 Mn |